Fujifilm Diosynth Biotechnologies U.S.A (FDBU) announced on Dec. 18, 2014 that it completed the acquisition of Kalon Biotherapeutics, a biopharmaceutical CMO formed by The Texas A&M University System in 2011. The agreement came to the publics attention in October 2014 when FujifilmOriginal Article
You may also like
Pharmaceutical Sales Customer Engagement –...
AstraZeneca’s Polyneuropathy Treatment Recommended...
Designing a Strategic Roadmap for Seamless Product...
AAPS PharmSci 360: LBFs and Tackling Oral Biologic...
CHMP Gives Positive Opinion to Novo Nordisk Hemophilia...
GSK, Cambridge to Partner on R&D for Kidney and...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.